4 terminated. 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 4 | Terminated 4 |
Follow Dyskinesias: new trials by email Literature Review of Dyskinesias trials Research Report on Dyskinesias
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation Haloperidol + lorazepam, Loxapine - Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use | Phase 4 | Terminated | University of Arkansas | 2 | 2017-09-30 | 2018-06-11 |
| SALT Study (Switching to the Administration of Lithium Slow -Release Treatment) Lithium sulphate prolonged-release 660 mg, Lithium carbonate immediate-release 150 mg and 300 mg - Bipolar Disorder | Phase 4 | Terminated | Aziende Chimiche Riunite Angelini Francesco S.p.A | 85 | 2017-03-28 | 2020-01-10 |
| Efficacy and Safety of Two Different Botulinum Toxin Type A Treatments for Moderate to Severe Cervical Dystonia botulinum toxin type A - Spasmodic Torticollis | Phase 4 | Terminated | Allergan | 54 | 2007-06-01 | 2011-12-16 |
| Safety Study of Galantamine in Tic Disorders galantamine - Tourette's Syndrome, Motor Tic Disorder | Phase 4 | Terminated | Parkinson's Disease and Movement Disorders Center | 1 | 2005-09-01 | 2009-08-25 |
Bipolar Disorder (1) · Psychomotor Agitation (1) · Tic Disorders (1) · Tics (1) · Torticollis (1) · Tourette Syndrome (1) · Tremor (1)
Neurologic Manifestations (4) · Pathological Conditions, Signs and Symptoms (4) · Signs and Symptoms (4) · Nervous System Diseases (3) · Mental Disorders (2) · Aberrant Motor Behavior in Dementia (1) · Basal Ganglia Diseases (1) · Behavior (1) · Behavioral Symptoms (1) · Bipolar and Related Disorders (1) · Brain Diseases (1) · Central Nervous System Diseases (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Dystonia (1)
Botulinum Toxins, Type A (1) · Galantamine (1) · Haloperidol (1) · Lorazepam (1) · Loxapine (1) · abobotulinumtoxinA (1)
Allergan (1) · Aziende Chimiche Riunite Angelini Francesco S.p.A (1) · Parkinson's Disease and Movement Disorders Center (1) · University of Arkansas (1)
United States (2) · Argentina (1) · Australia (1) · India (1) · Italy (1)
Donald S Higgins, M.D. (1) · Michael P Wilson, MD (1)
2016 (1)